Medicare is a cornerstone of health insurance for many Americans, yet it falls short in covering long-term care needs. This ...

A $28,000-a-year Alzheimer's drug will have its coverage limited by Medicare. The Centers for Medicare and Medicaid Services announced the limitations on Tuesday as questions remain over Biogen ...

Even though serious mental illness is no less chronic a condition than diabetes, Medicare beneficiaries are currently limited ...

FDA-approved Alzheimer’s drugs will be covered by Medicare, with some limitations, CMS says ... Medicare restricted coverage of Aduhelm to those enrolled in qualifying clinical trials last year, ...

Original Medicare has no limit on how much one will pay, but Medicare Advantage does cap the costs. ... She was very healthy and didn’t want to pay for more coverage she wouldn’t need.

Medicare gained the upper hand on Thursday when it released its final decision to limit coverage of the FDA-approved drug. To recap: The FDA gave the green light to Aduhelm (aducanumab) in June 2021.

Medicare officials announced on Thursday that the health insurance program for older Americans will sharply limit coverage of a costly and controversial new Alzheimer's drug.

Medicare’s coverage decision is considered pivotal to the future of Aduhelm, which is priced at $28,200 a year per patient. Roughly 80 percent of the patients eligible for the drug are old ...

Ever since Medicare proposed to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm, the agency has been deluged with impassioned pleas. Groups representing patients insisted ...

Medicare next year is also expanding eligibility for some low-income beneficiaries to qualify for low- or zero-premium drug coverage that comes with no deductibles and lower copayments, according ...

Medicare's 2025 enrollment began Tuesday and runs through Dec. 7. ... Consumers whose prescription drug costs exceed Medicare's catastrophic coverage limit will get a big break in 2025.